177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a pilot study to assess the safety and measure image-based absorbed dose of
177Lu-P17-087/177Lu-P17-088 in patients with metastatic castration-resistant prostate cancer
(mCRPC) who will undergo radioliagnd therapy using 177Lu-P17-087/177Lu-P17-088. All patients
underwent whole-body 68Ga-PSMA PET/CT for selection and accepted intravenous injection with
single dose 1.1 GBq (30 mCi) of 177Lu-P17-087/177Lu-P17-088 within one week, then monitored
at 3, 24, 48, 72 and 168 h after 177Lu-P17-087/177Lu-P17-088 administration with serial whole
body planar and SPECT/CT imaging.